A phase 0, exploratory study of the pharmacodynamics of a single intratumoral dose of
IMCgp100, a monoclonal T cell receptor anti-CD3 scFv fusion protein, in subjects with
advanced unresectable melanoma to assess the safety and pharmacodynamic properties of single
intratumoral doses of IMCgp100 in the setting of advanced unresectable melanoma. Six patients
will be enrolled to complete the study over approximately 12-15 months.